SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

The iShares Silver Trust is experiencing a parabolic surge, fueled by escalating industrial demand for silver in new technologies and anticipation of China's upcoming export restrictions. Community discussion highlights a potential short squeeze and belief that long-term price suppression is ending, though some anticipate a sharp correction after such an aggressive run.

BYTE is a novel meme token that creatively intertwines the worlds of cryptocurrency and popular culture. Inspired by Grok's answer to "What would you name your dog?", Grok answered, 'Byte.' When Grok was asked who created Byte, it says he was created by the xAI team lead by Elon Musk as a gift to Grok AI to keep him company in the metaverse. BYTE serves as a playful reference to the unit of digital information, as well as a nod to the AI's technological nature. Distinctively, Byte acts as a gateway towards Ai adoption and stands out in the crypto space due to its zero-tax policy, a feature that is increasingly appealing to many investors. Additionally, it upholds the principles of transparency and investor trust by having its liquidity permanently burned and the contract ownership renounced. This ensures that Byte remains a community-driven project, with its fate firmly in the hands of its holders. The combination of a playful theme, generative AI, and a nod to a tech icon makes Byte an intriguing addition to the meme token ecosystem, especially AI related meme coins.  Through pioneering AI this story has grown more and more robust and continues to evolve, Byte pledges its dedication to community efforts and and has consistently appeared in the Top 10 of LunarCrush’s social engagement leaderboards on multiple occasions.

BYTE

BYTE CRYPTO is generating significant community buzz, with enthusiasts proclaiming it "the chosen one" and positioning it as Grok's anticipated AI companion in the digital space. The conversation centers on its potential as the future of artificial intelligence within crypto, encouraging holders to "byte the dip" and maintain their positions for long-term prospects.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending due to its incredibly active and conviction-driven community, which passionately champions the "OG meme" narrative of Rage Comics. This dedicated base is focused on continually building and expanding the ecosystem with projects like RageMaker and RageGames, aiming to onboard new users into the crypto space. The community collectively views RAGE as significantly undervalued, anticipating substantial long-term growth and widespread recognition.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

NuScale Power (SMR) is experiencing extreme volatility and divided investor sentiment following a significant price correction, driven by concerns over ongoing institutional share sales and an upcoming vote on potential share dilution. However, a segment of the community views the current dip as a buying opportunity, emphasizing NuScale's NRC-certified SMR technology as crucial for addressing the escalating energy demands of AI data centers and future global power needs.

Universe Pharmaceuticals, Inc. is a pharmaceutical company. The firm is focused on the manufacturing, marketing, sales, and distribution of traditional Chinese medicine derivative products. It also sells biomedical drugs, medical instruments, traditional Chinese medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. The company was founded on March 2, 1998 and is headquartered in Ji'an, China.

Universe Pharmaceuticals INC

Universe Pharmaceuticals (UPC) is generating buzz due to its extremely low public float, which is fueling speculative trading and high volume spikes. Community discussion is sharply divided, with some anticipating a significant short squeeze and highlighting the company's robust financial standing, while others warn of its history as a volatile Chinese micro-cap.

Yee is a community based memecoin with one mission: to fight Pepe again. Made to honor the iconic meme rivalry we all know and love.  The Yee Legend  [Filed by: Yee’s Archivist & Legal Representative]  There’s something the meme world refuses to talk about: Pepe the Frog stole Yee the Dino’s entire launch plan.  Yee had been preparing for his comeback for months, but Pepe launched two weeks earlier, hijacking Yee’s concept and selling it as his own.  The charges? Meme theft, intellectual forgery, and historical erasure.  Yee’s official contract was filed in April 2023, right after Pepe’s surprise drop. This wasn’t timing—it was theft. The archives are about to open, and history is about to be corrected

Yee Token

YEE CRYPTO is experiencing significant upward momentum, driving overwhelmingly bullish community sentiment that positions it as a key player in the ongoing "ETH season." The community is actively discussing its potential as the "fuel of the future" for Ethereum and a return to original memecoin culture, with many encouraging participation in its perceived "unstoppable" ascent.

GSI Technology, Inc. engages in the design, development and marketing of memory products primarily for the networking, and telecommunications markets. Its product includes Static Random Access Memory, or SRAM, which incorporated in networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations and network access equipment. It also offers services to the ongoing needs of the military, industrial, test and measurement equipment, automotive and medical markets for SRAMs .The company was founded by Lee-Lean Shu and Robert Yau in March 1995 and is headquartered in Sunnyvale, CA.

GSI Technology Inc

GSI Technology is trending amid significant trading volume, driven by renewed investor interest in its compute-in-memory (CIM) APU technology following sector developments. The community is actively debating the company's potential as a disruptive force in edge AI, with discussions centering on its low-power Gemini chips for defense, drone, and satellite applications, including partnerships. Anticipation for upcoming multi-modal large language model benchmarks is also fueling conversation around GSIT's unique position in the evolving AI hardware landscape.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending after receiving FDA approval for YARTEMLEA, the first and only treatment for a critical transplant complication, generating significant bullish sentiment within the community. Investors are actively discussing the stock's long-term potential, bolstered by a substantial deal with Novo Nordisk, a de-risked balance sheet, and expectations for strong commercialization and analyst upgrades.

Telcoin is a multi-national fintech company  integrating blockchain technology, telecommunications, and digital banking to revolutionize global finance. It aims to provide borderless, instant, and affordable financial services to mobile phone users worldwide. Telcoin offers the Telcoin Wallet, a multi-signature DeFi wallet supporting more than 100 digital assets and remittances to eWallets and bank accounts globally. Telcoin is regulated as a Virtual Asset Service Provider in the EU (Lithuania) and Argentina, a Major Payment Institution in Singapore, and a Money Services Business in the US, Canada, and Australia.   Telcoin is designed to complement telecom, mobile money, and e-wallet partners globally with both traditional fiat and blockchain transaction rails that underpin our fast and affordable digital financial service offerings. Telcoin combines the best parts of the burgeoning DeFi ecosystem with our compliance-focused approach to each market, ensuring that the company takes on a fraction of traditional financial counterparty, execution, and custody risks.  The Telcoin Association is a Swiss non-profit organization domiciled in Lugano, Switzerland and is governed by a decentralized group of Miner Councils that run the various aspects of the Telcoin Platform, including the management of the Telcoin (TEL) token. Read more about the Telcoin Association [here](https://www.telcoin.org).

Telcoin

Telcoin ($TEL) is trending amidst high anticipation for the finalization and opening of its Digital Asset Bank in Nebraska, which received charter approval and is poised to launch eUSD, a regulated, bank-issued US dollar stablecoin. The community is actively discussing Telcoin's compliance-first approach and its potential to bridge traditional finance with decentralized finance, often drawing comparisons to early growth stages of other established cryptocurrencies. Many perceive Telcoin as a foundational player in regulated digital cash and a significant long-term opportunity.

A SPAC III Acquisition Corp. is a blank check company. The company was created for the purpose of effecting a merger, asset acquisition, share purchase, reorganization or similar business combination. The company was founded on September 3, 2021 and is headquartered in Hong Kong.

A SPAC III Acquisition Corp. - Ordinary Shares - Class A

Alpha Capital Acquisition Co - Ordinary Shares - Class A

Alpha Capital Acquisition Co (ASPC) is trending due to an extraordinary surge in trading volume and price, sparking intense community discussion about a potential short squeeze. Fueling the conversation are mentions of its low float and extremely high borrow rates, leading many to speculate on significant further upward movement, while others express caution regarding its volatile nature.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

HCW: We reiterate our Buy rating and $12 price target on $EPRX following new data from Cohort 9 of the RESOLVE trial, the first group to receive the highest planned dose of EP-104GI at 8 mg per injection. Patients in this cohort achieved the largest improvements in tissue health and eosinophil reduction observed to date, continuing the dose-response relationship seen in earlier groups. 
 
The RESOLVE Safety Committee and members of the company&#39;s Clinical Advisory Board endorsed advancing this dose into the Phase 2b portion of the study. 
 
Importantly, the treatment remained well tolerated, with no serious adverse events or cases of candidiasis reported. The durable twelve-month efficacy and validation of once-yearly dosing further expands the commercial potential of EP-104GI in a U.S. 
 
EoE market exceeding one million patients. We believe this new data should drive a positive stock re-rating, as EPRX&#39;s ~$212M market capitalization continues to undervalue the commercial potential of EP-104GI.

Gary Reitz

Cantor y&#39;day reiterated $EPRX Overweight-$11 
$SNY 
Cantor Fitzgerald said in its note: 
We already knew about the emerging durability profile, indicating that EP-104GI can support efficacy out to ~12 months based on Cohort 5-7 data. Today, we saw just how deep the tissue responses could be, as early as week 4, in the highest dose. 
 
The combination of 1) adding the second Phase 2b dose of 8 mg per injection and 2) upsizing the Phase 2b trial gives us more confidence that the company will see significant benefit vs. placebo. 
 
As we highlighted in our recent note (HERE), we know that steroids work in EoE, and today&#39;s results underscore how important it is to solve the delivery problem (targeting steroid to the esophagus without raising overall drug exposure). 
 
We expect the stock to be up tomorrow, as EPRX is still trading at a steep discount to our conservative peak U.S. annual sales estimates of~$900M.

StockTwits Web

Eupraxia Pharmaceuticals Inc

Sanofi-Aventis

Quantumup

HCW: We reiterate our Buy rating and $12 price target on 

 following new data from Cohort 9 of the RESOLVE trial, the first group to receive the highest planned dose of EP-104GI at 8 mg per injection. Patients in this cohort achieved the largest improvements in tissue health and eosinophil reduction observed to date, continuing the dose-response relationship seen in earlier groups. 
 
The RESOLVE Safety Committee and members of the company's Clinical Advisory Board endorsed advancing this dose into the Phase 2b portion of the study. 
 
Importantly, the treatment remained well tolerated, with no serious adverse events or cases of candidiasis reported. The durable twelve-month efficacy and validation of once-yearly dosing further expands the commercial potential of EP-104GI in a U.S. 
 
EoE market exceeding one million patients. We believe this new data should drive a positive stock re-rating, as EPRX's ~$212M market capitalization continues to undervalue the commercial potential of EP-104GI.